Valeant pulls Parkinson's drug on safety fears

Valeant Pharmaceuticals has pulled the Parkinson's drug pergolide, sold as Permax, after regulators determined that the drug was associated with high rates of heart valve damage. Permax is made by Valeant and two generic versions are also on the market. The therapy is a dopamine agonist and is used as a first-line treatment against Parkinson's. Valeant's move came at the request of the FDA, which has been tracking heart valve damage linked to the drug since 2002. Permax has been on the market for 19 years.

- check out the release on the withdraw from the FDA
- here's the report from HealthDay

Related Articles:
Parkinson's drugs linked to heart valve damage. Report
Valeant hep C drug fails pivotal trial, again. Report
Valeant to out-license programs in restructuring. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.